- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- ASTX727 Oral DNMT inhibitor (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- AZD5363 PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
Our partners are advancing several compounds in clinical trials that were the outcome of previous drug discovery collaborations with Astex. The responsibility for developing these products is with our partners.
| Discovery | Phase 1 | Phase 2 | Phase 3 | Marketed |
|---|
Kisqali® (ribociclib)
CDK4/6 inhibitor (Oncology)
Partner: Novartis
| . | . | . | . | . |
Balversa® (erdafitinib)
FGFr inhibitor (Oncology)
Partner: Janssen
| . | . | . | . | . |
AZD5363 (capivasertib)
PKB/Akt Inhibitor (Oncology)
Partner: AstraZeneca
| . | . | . | . |
Multiple Targets and Therapeutic Areas
Partner: GlaxoSmithKline
| . | . |